AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

We recently published a list of 11 Best Bear Market Stocks To Invest In Now. In this article, we are going to take a look at ...

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $170.67 which represents a slight increase of $1.47 or 0.87% from the prior close of $169.2. The stock opened at $170.46 and touched a ...

AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st.

Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $171.56 which represents a decrease of $-2.14 or -1.23% from the prior close of $173.7. The stock opened at $172.88 and touched a ...

Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular ...